

SELECTED OPPORTUNITIES IN ONCOLOGY

Anti-neurotensin antibody for the treatment of non small cell lung cancer

(BIO07563, BIO14015, BIO14016 & BIO17665)

ANTI-NEUROTENSIN ANTIBODY FOR THE TREATMENT OF NON SMALL CELL LUNG CANCER

Product factsheet Preclinical

- Target: Neurotensin (NTS)
- Application: non small cell lung cancer (NSCLC)
- Potential Product :a proprietary neurotensin antibody (humanization of this antibody is ongoing)

Rationale:

- High expression of NTSR1 is associated with poor prognosis in NSCLC and worse sensitivity to platinum-base chemotherapy
- NTS antibody ameliorates cisplatin and SOC treatments in a mouse model of NSCLC
- NTS antibody decreases number and size of metastases in a mouse model of NSCLC
- NTS antibody increases weight and activity in mice
- NTS KO or NTSR1 KO have no overall abnormal phenotype under physiological conditions


Patent Applications and publication :

- Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody Wu Z. et al. Cancer Letters 444 (2019) 147–161
- PCT/EP2009/054395: Methods for the treatment, the prognostic assessment and the staging of non-small cell lung cancer
- PCT/EP2015/062168: Anti-neurotensin antibodies and the uses thereof
- PCT/EP2015/062079:: Anti-neurotensin long fragment antibodies and the uses thereof
- PCT/EP2019/073991 :Use of an inhibitor of NTSR1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof




Proof of concept Preclinical


High expression of NTSR1 is associated with poor prognosis in NSCLC and worse sensitivity to platinum-base chemotherapy



138 Stage I lung adenocarcinomas with no post surgery adjuvant or neo-adjuvant therapy




389 Stage I to Stage III lung adenocarcinomas





ANTI-NEUROTENSIN ANTIBODY FOR THE TREATMENT OF NON SMALL CELL LUNG CANCER

Proof of concept Preclinical

NTS antibody ameliorates cisplatin and SOC treatments in vivo









Proof of concept Preclinical


NTS antibody decreases number and size of metastases




Proof of concept Preclinical

NTS antibody increases weight and activity







ANNE.COCHI@INSERM-TRANSFERT.FR

